<DOC>
	<DOCNO>NCT00598208</DOCNO>
	<brief_summary>The primary objective trial investigate dose -response relationship single injection Org 38286 initiate multifollicular growth first seven day control ovarian hyperstimulation ( COH ) protocol IVF ICSI .</brief_summary>
	<brief_title>A Phase 2 , Trial Investigate Dose-Response Relationship Single Injection Org 36286 ( Corifollitropin Alfa ) Initiate Multiple Follicular Growth Controlled Ovarian ( Study 38826 ) ( P06055 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Females couple indication COH IVF ICSI ; &gt; =18 &lt; =39 year age time sign informed consent ; BMI &gt; =18 &lt; =29 kg/m^2 ; Normal menstrual cycle length : 2435 day ; Ejaculatory sperm ( use donate and/or frozen sperm allow ) ; Willing able sign inform consent . History of/or current ( treat ) endocrine abnormality ; History ovarian hyperstimulation syndrome ( OHSS ) ; History of/or current polycystic ovary syndrome ( PCOS ) current polycystic ovary accord USS ( least 10 follicle 28 mm ovary ) ; More three unsuccessful COH cycle since last establish ongoing pregnancy ( applicable ) ; History non low ovarian response FSH/hMG treatment ; Any clinically relevant hormone value outside reference range early follicular phase ( menstrual cycle day 27 ) measure local laboratory ( FSH , LH , E2 , P , total T , TSH prolactin ) : Any clinically relevant abnormal laboratory value ; Less 2 ovary ; Any ovarian and/or abdominal abnormality interfere ultrasound examination ; Contraindications use gonadotropin ( e.g . tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) ; Epilepsy , diabetes , cardiovascular , gastrointestinal , hepatic , renal , pulmonary , abdominal disease ; History presence alcohol drug abuse within 12 month prior sign informed consent ; Previous use Org 36286 ; Use hormonal preparation within 1 month prior randomization ; Hypersensitivity Org 32489 ( Puregon® ) and/or Org 37462 ( Orgalutran® ) and/or Pregnyl® component ; Administration investigational drug within three month prior sign inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>In-vitro fertilization</keyword>
</DOC>